Lily Pham is an Assistant Professor of Neurology at the University of Maryland School of Medicine, specializing in neuro-oncology. She treats primary brain cancers and neurological complications of cancer. Education: Duke University (2012), Virginia Tech Carilion School of Medicine (2016) Training: Neurology residency at Baylor College of Medicine (2020), Neuro-Oncology fellowship at MD Anderson Cancer Center (2022) Her research focuses on clinical trial development for novel brain tumor therapies, particularly targeted treatments for high-grade glioma and meningioma. She combines clinical practice with chemotherapy prescription and intrathecal delivery techniques.
Karan S Dixit, MD is an Assistant Professor in the Department of Neurology at Northwestern University's Feinberg School of Medicine, specializing in neuro-oncology and serving as Fellowship Director for the education program. His educational background includes: MD from Louisiana State University (2011) Internal Medicine Internship at University of Illinois at Chicago (2012) Neurology Residency and Chief Medical Resident at University of Illinois at Chicago (2015) Neuro-Oncology Fellowship at Northwestern University McGaw Medical Center (2016) He maintains board certification in Neurology (American Board of Psychiatry and Neurology) and Neuro-Oncology (United Council for Neurologic Subspecialties). Dr. Dixit's research centers on CNS lymphoma, lower-grade gliomas, and glioblastoma, with emphasis on novel therapies for treatment resistance. He investigates biomarkers for disease monitoring and explores neurocognitive decline mechanisms related to neural connectivity changes during CNS cancer treatment. His work bridges clinical neurology with translational oncology through molecular diagnostics and therapeutic innovation. His 2025 publications reveal three critical research trajectories: molecular characterization of glioma mutations (TERT/IDH), liquid biopsy applications for CNS lymphoma diagnosis, and repurposing antiseizure drugs with antineoplastic potential. These studies collectively advance precision medicine approaches for treatment-resistant CNS malignancies. Professional recognition includes: John A Kessler Teaching Award (2022, 2019) NeuroNEXT Fellow (2020) Society of Neuro-Oncology Clinical Trials Course (2019) University of Illinois Teaching Excellence Awards (2014-2015) As Fellowship Director, Dr. Dixit mentors neuro-oncology trainees while leading three active clinical trials: Vorasidenib/Pembrolizumab for IDH-mutant glioma (NCT05484622), NX-5948 BTK degrader for CNS lymphoma (NCT05131022), and emavusertib for relapsed PCNSL (NCT03328078). His industry collaborations include Bluprint Oncology Concepts and Servier Pharmaceuticals for therapeutic development. He maintains active membership in the Feinberg Academy of Medical Educators, American Neurological Association, American Academy of Neurology (Neuro-Oncology Section), American Society of Clinical Oncology, and Society of Neuro-Oncology, collaborating through Northwestern Medicine's Robert H. Lurie Comprehensive Cancer Center and Clinical and Translational Sciences Institute.
Dr. Sameer A Ansari, MD, PhD is a Professor of Radiology (Interventional Neuroradiology), Neurological Surgery, and Neurology at Northwestern University's Feinberg School of Medicine. He holds appointments in multiple departments reflecting his interdisciplinary expertise in neurovascular interventions and stroke care. His educational background includes: MD from Jefferson Medical College, Thomas Jefferson University (2000) PhD from College of Graduate Studies, Thomas Jefferson University (2000) Radiology Residency at University of Illinois at Chicago (2005) Neuroradiology Fellowship at University of Michigan Health System (2006) Interventional Neuroradiology Fellowship at University of Michigan Health System (2008) Dr. Ansari is board certified in both Neuroradiology and Diagnostic Radiology by the American Board of Radiology. His primary research interests focus on endovascular treatment of neurovascular diseases, particularly advanced MRI techniques to optimize patient selection for acute ischemic stroke interventions and intracranial atherosclerotic disease treatments. He has published extensively on stroke thrombectomy outcomes, intracranial aneurysm management, and neurointerventional oncology. His recent publications (2025) demonstrate significant contributions across multiple domains including probabilistic modeling for stroke outcomes prediction, racial disparities in aneurysm treatment, novel approaches to medium vessel occlusion, and the emerging field of neurointerventional oncology. His work frequently leverages the NeuroVascular Quality Initiative-Quality Outcomes Database (NVQI-QOD) registry to generate real-world evidence. Dr. Ansari maintains active leadership roles in professional societies: Scientific Exhibits Committee-Interventional, ASNR (2010-Present) Session Moderator-Adult Brain: Vascular, Intracranial, ASNR (2010-Present) AHA/ASA Abstract Grading Subcommittee, International Stroke Meeting (2010-Present) Presentation Award Committee-Interventional, ASNR (2010-Present) His professional society memberships include the American Heart/Stroke Association, American Society of Neuroradiology, Society of Neurointerventional Surgery, American Roentgen Ray Society, American University Radiologists, American College of Radiology, and Radiological Society of North America. In 2024, he served on boards for the American Board of Radiology, American College of Radiology, American Heart Association, and multiple medical device companies including Boston Scientific, Medtronic, and MicroVention. Dr. Ansari's clinical work focuses on the endovascular treatment of neurovascular diseases, with particular expertise in acute stroke intervention and complex cerebrovascular disorders. His research bridges clinical practice with advanced imaging techniques to improve patient outcomes in neurointerventional procedures.
Sandeep Kumar Mishra, PhD, is an Associate Research Scientist in the Department of Radiology & Biomedical Imaging at Yale School of Medicine, where he holds a primary appointment in the Magnetic Resonance Research Center within the Division of Bioimaging Sciences. He completed his doctoral training at Pondicherry University (2017) and finished post-doctoral research at Yale in 2024 before transitioning to his current research-intensive faculty role. Education: PhD, Pondicherry University – 2017 Post-doctoral Associate, Yale University – 2024 Research Focus: Mishra’s work integrates multinuclear magnetic resonance spectroscopy, responsive paramagnetic probes, and nano-constructs to quantify the tumor microenvironment. Major themes include in-vivo mapping of interstitial pH and sodium gradients in gliomas, development of Fe(II)/Co(II)/Ni(II)-DOTA tetraglycinate complexes for simultaneous pH–temperature sensing, and engineering dual-modal nano-agents that couple MR angiography with therapeutic delivery (chemo-photothermal, cryo-ablation, MMP inhibition). Publication Trends: Across 28 peer-reviewed articles (2016-2025) he demonstrates a sustained trajectory in cancer imaging, moving from theranostic nanoparticles toward sophisticated spectroscopic imaging of tumor acid–base and ionic homeostasis, with increasing translational orientation involving rodent glioma and hepatocellular carcinoma models. Collaborations & Affiliations: He is embedded in Yale’s inter-disciplinary MR research ecosystem, collaborating recurrently with faculty in Radiology, Biomedical Engineering, and the Magnetic Resonance Research Center (D. Coman, F. Hyder, P. Herman, J. Verhagen, J. Santana, A. Shewarega). Contact: sandeepkmishra11@gmail.com | Magnetic Resonance Research Center, 300 Cedar Street, New Haven, CT 06519, USA
Katsuhito Yasuno is a Research Scientist in the Department of Neurosurgery at Yale School of Medicine. He works within the Gunel Lab, focusing on neurogenetic research related to brain disorders, vascular conditions, and tumors. His work involves genomic analyses and molecular studies to understand the genetic basis of various neurological conditions. Education: Postdoctoral Fellow, Japan Science and Technology Corporation (2008) Postdoctoral Fellow, Japan Biological Informatics Consortium (2006) Postdoctoral Fellow, Tokai University School of Medicine (2004) PhD in Theoretical Physics, Tokyo Institute of Technology (2002) MS in Theoretical Physics, Tokyo Institute of Technology (1999) BS in Physics, Tokyo Metropolitan University (1997) Dr. Yasuno's research spans multiple areas of neurogenetics and molecular neuroscience. His primary interests include epidemiologic factors and methods related to brain tumors (particularly glioblastoma and meningioma), intracranial aneurysms, nervous system diseases and malformations, and vascular diseases. His physics background contributes to sophisticated analytical approaches in genetic research. His publication record shows consistent contributions to understanding the genetic mechanisms underlying neurological disorders, with recent work focusing on meningioma genetics, brain malformations, and vascular disorders. The research demonstrates a progression from basic genetic discovery to translational applications, with particular emphasis on molecular pathways that could serve as therapeutic targets. Dr. Yasuno collaborates extensively with leading researchers in the field, most notably with Dr. Murat Günel (28 common publications) and Dr. Kaya Bilguvar (34 common publications). His work involves both computational analysis and laboratory validation of genetic findings. As part of the Gunel Lab, Dr. Yasuno contributes to the lab's three major research interests: developmental neurogenetic disorders, neurovascular disorders, and brain tumor biology. The lab utilizes advanced genomics techniques and bioinformatic analysis for gene discovery followed by functional studies.
University of California, San FranciscoUnited States
Jacob Young, MD, is an Assistant Professor in the Department of Neurological Surgery at the University of California, San Francisco (UCSF) School of Medicine and a Principal Investigator in the UCSF Brain Tumor Center. His clinical practice focuses on neurosurgical management of adult brain tumors including gliomas, metastatic tumors, and meningiomas, utilizing advanced brain mapping techniques to preserve critical motor, language, and sensory functions during resection. Dr. Young's educational background includes a BS in Neuroscience from Duke University (2012), an MD from the University of Chicago Pritzker School of Medicine where he was elected to Alpha Omega Alpha Honor Medical Society (2017), and a neurosurgery residency at UCSF (2017-2024). His research program integrates laboratory investigations with clinical trials to address fundamental challenges in brain tumor treatment. His primary research interests center on understanding glioblastoma immune microenvironment dynamics and developing innovative therapeutic strategies. Key focus areas include: First-in-human clinical trials of novel immunotherapies Focused ultrasound-mediated blood-brain barrier disruption to enhance drug delivery Longitudinal molecular profiling of tumor evolution during treatment AI-driven tools for patient care navigation and clinical trial assessment Prospective outcomes research through the RANO resect group and NeuroPoint Alliance His work bridges fundamental tumor biology with translational applications to overcome treatment resistance. Analysis of Dr. Young's 15 most recent publications (2023-2025) reveals a strong emphasis on surgical innovation, tumor immunology, and molecular characterization. Key trends include: development of prognostic classification systems for resection extent, investigation of glioma-neuronal circuit interactions driving immunosuppression, and optimization of drug delivery strategies. His collaborative work within the RANO consortium establishes evidence-based surgical guidelines while his lab's focus on microenvironmental factors informs next-generation immunotherapies. Dr. Young has received significant recognition including: Chan-Zuckerberg Physician Scientist Fellowship (2021-2022) ASCO Young Investigator Award (2022-2023) Andrew J. Lockhart Focused Ultrasound Fellowship (2023) Multiple Harold Rosegay Teaching Awards from UCSF Howard Naffziger Award for Clinical Excellence His research is supported by NIH, NCI, Focused Ultrasound Foundation, and AANS grants. As lab director, Dr. Young mentors a diverse team including PhD candidates like Edward Valenzuela (DSCB program) and specialists in immunology and neuro-oncology. His lab participates in the RANO resect group, ENCRAM research program, and NeuroPoint Alliance to advance clinical protocols. Current projects include developing intraoperative focused ultrasound prototypes, single-cell analysis of tumor evolution, and AI tools for patient navigation through care pathways. Future work focuses on translating microenvironment discoveries into combination therapies targeting treatment resistance mechanisms.
Sophia Lunt is a Professor in the Department of Biochemistry & Molecular Biology and Chemical Engineering & Materials Science at Michigan State University , where she has been since 2015 (Assistant Professor 2015-2021, Associate Professor 2021-2025, Professor 2025-present). She leads the Lunt Lab , focusing on cancer metabolism , particularly metabolic reprogramming in tumor proliferation, heterogeneity, and metastasis . Her work combines mass spectrometry , genetic cancer models , cell biology , and fluorescent agents to develop targeted cancer therapies . Ph.D. (2010) & B.S. (2005) in Chemistry Postdoctoral Fellow at MIT (2010-2015) NSF CAREER awardee (2019) 20+ peer-reviewed publications since 2007 Research Focus : Cancer metabolism (Warburg effect, PHGDH heterogeneity, TIGAR regulation) Photodynamic therapy (counterion-tuned agents, metal halide nanoclusters) Metabolomics (tumor-immune interactions, microbiome effects) Selected Scientific Awards : 2022 MSU College of Natural Science Teacher-Scholar Award 2022 MSU BMB Teaching Award 2020 MANA Young Investigator Award 2019 NSF CAREER & METAvivor Early Career Investigator Awards Her teaching includes BMB 101: Frontiers in Biochemistry (curriculum overhaul for freshman success) and BMB 461: Advanced Biochemistry I , covering metabolic regulation and pathways.
University of California, Los AngelesUnited States
Robert M Prins is a Professor of Neurosurgery and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). He leads the Robert Prins Lab at UCLA, which focuses on developing novel immunotherapies for brain tumors, particularly glioblastoma. Dr. Prins received his B.S. in Kinesiology (1992) and M.S. in Physiological Science (1996) from UCLA, followed by a Ph.D. in Anatomy & Immunology from the Medical College of Virginia/Virginia Commonwealth University (2001). He completed fellowships in Tumor Immunology at Cedars-Sinai Neurosurgical Institute (2002) and Brain Tumor Immunotherapy at the David Geffen School of Medicine at UCLA (2003). His research focuses on brain tumor immunology and immunotherapy, with particular emphasis on dendritic cell vaccination, immune checkpoint inhibitors, and adoptive T cell therapy for glioblastoma. Dr. Prins has secured multiple NIH grants as Principal Investigator, including current funding for neoadjuvant checkpoint blockade for recurrent glioblastoma (R01CA267726) and identification of neoantigen-specific T cells for GBM immunotherapy (R01CA222695). Dr. Prins' work has demonstrated the potential of neoadjuvant immunotherapy approaches for glioblastoma, showing that early administration of immune checkpoint inhibitors before surgery can induce significant immune responses within the tumor microenvironment. His research has also explored mechanisms of immunotherapy resistance in brain tumors and strategies to overcome these barriers. He has published extensively in high-impact journals including Nature Medicine, Nature Communications, and Neuro-Oncology, with his most recent work focusing on spatial immune profiling of glioblastoma, CAR-T cell therapies, and epigenetic approaches to enhance immunotherapy efficacy. Dr. Prins is actively involved in clinical translation of his research findings, with several clinical trials underway at UCLA to evaluate novel immunotherapeutic approaches for patients with malignant brain tumors.
The University of Texas MD Anderson Cancer CenterUnited States
Pratip K. Bhattacharya, Ph.D. , is an Associate Professor in the Department of Cancer Systems Imaging and the Department of Imaging Physics at The University of Texas MD Anderson Cancer Center, with a joint appointment in the Graduate School of Biomedical Sciences at The University of Texas Health Science Center. He is a principal investigator leading the Bhattacharya Laboratory, dedicated to advancing magnetic resonance imaging (MRI) through hyperpolarization techniques for applications in cancer and cardiovascular diseases. His research focuses on developing real-time metabolic and molecular imaging methods using hyperpolarized 13 C and 15 N-labeled compounds and silicon nanoparticles. These innovative probes significantly enhance MRI sensitivity, enabling non-invasive assessment of tissue metabolism and targeted imaging. His lab's work spans three primary areas: real-time metabolic MR imaging, targeted molecular MR imaging with functionalized silicon nanoparticles, and high-resolution MR metabolomics. These efforts are aimed at improving disease diagnosis and therapy monitoring. Analysis of his recent publications reveals a strong and consistent focus on hyperpolarized MRI, particularly using silicon particles and metabolic tracers like succinate, to visualize cancer metabolism and cardiovascular conditions in vivo. His research integrates physics, chemistry, and biomedical engineering to create novel imaging tools with direct clinical translational potential. PHIP Hyperpolarization Dynamic Nuclear Polarization (DNP) Hyperpolarized Silicon Nanoparticles Real-Time Metabolic Imaging Cancer and Cardiovascular Imaging Theranostic Applications Dr. Bhattacharya actively mentors graduate students and postdoctoral fellows, including Saleh Ramezani, Jose Enriquez, Dontrey Bourgeois, and Kang-Lin Hsieh. He collaborates closely with physician-scientists, radiologists, and oncologists to ensure his imaging science innovations address critical clinical needs. His laboratory is supported by grant funding, facilitating the development of cutting-edge imaging technologies. The Bhattacharya Laboratory is a key component of the Division of Diagnostic Imaging at MD Anderson, fostering a collaborative environment for interdisciplinary research. The lab focuses on translating fundamental discoveries in hyperpolarization physics into practical tools for improving cancer care.
Xue Han is a Professor of Biomedical Engineering at Boston University (BU), affiliated with the Han Lab. His primary academic appointment is in the Biomedical Engineering department, with additional affiliations in Neuroscience & Neuroengineering, and Photonics & Optical Systems. He holds a PhD in Physiology from the University of Wisconsin-Madison and a B.S. in Biophysics from Beijing University, China. Dr. Han’s research focuses on addressing unmet medical needs in brain disorders by developing novel neuromodulation therapies. His work combines genetic, molecular, pharmacological, optical, and electrical tools to study neural circuit dynamics, with a particular emphasis on optogenetics and optical neural modulation. Key projects include pioneering light-based neuron silencing techniques and pre-clinical testing of neurotechnologies like transcranial ultrasound stimulation. His lab investigates how neural synchrony contributes to cognition and pathology, aiming to link neural activity to behaviors like movement, attention, and decision-making. His recent publications emphasize high-frequency electrical stimulation effects, membrane voltage imaging, and the impact of neuromodulation on brain rhythms. Notable themes include the role of PV neurons in cortical coding, ultrasound-based neuron activation, and the interplay between neural oscillations and disease states. While no formal awards are listed, his prolific output highlights contributions to neurotechnology and systems neuroscience. Dr. Han’s lab develops advanced imaging tools like targeted-illumination confocal microscopy (TICO) and collaborates on projects involving exosome-mediated therapies and brain-computer interfaces. Ongoing work explores translational applications of neurophotonic tools and the mechanistic basis of neuromodulation therapies for disorders like Parkinson’s and epilepsy.
Dr. Summer Han serves as Associate Professor of Medicine, Neurosurgery, and Epidemiology at Stanford University School of Medicine. She leads research through the Quantitative Sciences Unit (QSU) in the Biomedical Informatics Research Division of the Department of Medicine and maintains joint appointments in the Department of Neurosurgery. Her work bridges statistical methodology development with clinical applications in cancer screening and neuroscience. Her research program focuses on statistical genetics, molecular epidemiology, and risk prediction modeling for complex diseases. Key areas include developing novel methods for analyzing high-dimensional genomic data, creating dynamic risk prediction models under competing risks, and establishing evidence-based cancer screening strategies. Her team integrates genetic, environmental, and clinical factors to improve early detection of lung cancer and second primary malignancies, with particular attention to reducing racial disparities in screening outcomes. Dr. Han's scientific contributions have been recognized through prestigious awards including the NCI R37 MERIT Award for Early-Stage Investigators and the Department of Medicine Teaching Award in Biomedical Informatics Research. Her team has developed impactful tools such as the SPLC-RAT for second primary lung cancer risk assessment and RAMBO for brain metastasis prediction in lung cancer patients. She actively mentors PhD students and postdoctoral fellows, with several former trainees securing faculty positions at institutions including Cornell University and IIT Roorkee. Current research initiatives include the Oncoshare-Lung database integrating EHRs from Stanford Health Care and 23+ Sutter Health sites across Northern California, and the Cancer Data Science Shared Resources Core which she co-directs at the Stanford Cancer Institute. NCI R37 MERIT Award (Early-Stage Investigator) 2022 Department of Medicine Teaching Award in Biomedical Informatics 2024 SCI Equity Impact Research Grant 2024 Neurosurgery Research Seed Grant Award Multiple NCI R01 grants (CA226081, CA282793) Her laboratory collaborates extensively across Stanford Medicine, working with thoracic oncologists, neurosurgeons, and epidemiologists to translate statistical innovations into clinical practice. Current projects address socioeconomic factors in cancer risk stratification, real-time physical activity monitoring in spine surgery recovery, and machine learning approaches for genomic data analysis.
Joseph N. Contessa, MD, PhD is an Adjunct Professor of Therapeutic Radiology and Pharmacology at Yale School of Medicine, where he serves as Director of Yale Medicine's Central Nervous System Radiotherapy Program. His clinical practice focuses on treating patients with brain tumors, head and neck cancers, and tumors at the base of the skull, including rare entities such as low-grade and malignant gliomas, ependymomas, high-grade meningiomas, hemangiopericytomas, paragangliomas, and schwannomas. Dr. Contessa's research spans multiple areas of cancer biology with a particular emphasis on molecular mechanisms of therapeutic resistance and novel approaches to radiosensitization. His work explores the role of N-linked glycosylation in cancer progression and treatment resistance, developing small molecule inhibitors targeting this pathway to overcome resistance to EGFR tyrosine kinase inhibitors. He also investigates targeted therapies for head and neck squamous cell carcinoma, molecular imaging of the epidermal growth factor receptor, and drug discovery through high-throughput screening approaches. Analysis of Dr. Contessa's recent publications reveals a consistent focus on the intersection of radiation oncology and molecular biology, particularly examining how glycosylation pathways influence cancer cell response to radiation and targeted therapies. His work spans basic science investigations into protein folding and quality control mechanisms to clinical applications in lung cancer, brain tumors, and head and neck cancers. A significant portion of his research explores how inhibiting specific glycosylation enzymes can sensitize tumors to radiation therapy. Dr. Contessa actively collaborates with leading researchers at Yale including Veronica Chiang (6 publications), Barbara Burtness (2 publications), Kimberly Johung (2 publications), and Scott Gettinger (2 publications). He serves as a Sub Investigator on the clinical trial 'Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer' (HIC ID 1603017333), which is scheduled for primary completion in June 2026. His laboratory work is closely integrated with clinical care through multiple Yale centers including the Brain Tumor Center, Gamma Knife Center, Head and Neck Cancers Program, and Yale Cancer Center. Dr. Contessa's research bridges basic science discoveries in protein glycosylation with clinical applications in radiation oncology, creating a translational pipeline from bench to bedside for patients with challenging malignancies.
Sameer Nath, MD, is an Associate Professor in the Department of Radiation Oncology at the University of Colorado Anschutz Medical Campus School of Medicine. He holds leadership roles as Vice Chair of Clinical Affairs, Clinical Practice Director at Anschutz Medical Campus, and Medical Director of Radiation Oncology at Highlands Ranch Hospital. Dr. Nath is board-certified in Radiation Oncology and practices at UCHealth Radiation Oncology and Rocky Mountain Gamma Knife Center. MD: University of California, San Diego School of Medicine (2010) Internship: University of California, San Diego (2011) Residency: Yale-New Haven Medical Center, Chief Resident in Radiation Oncology (2015) His research focuses on radiation therapy applications for prostate and lung cancers, brain metastases management, and immunotherapy-radiation combinations. He has pioneered work in stereotactic body radiation therapy (SBRT), tumor hypoxia, radiation pneumonitis prevention, and medical imaging innovations for treatment planning. Recent publications examine oligoprogressive prostate cancer management, radiation oncology nurse education, and deep learning applications in patient positioning. Dr. Nath's 15 most recent publications (2024-2017) demonstrate expertise in prostate cancer (4 articles), lung cancer (4 articles), brain metastases (4 articles), and medical imaging/education (3 articles). Key research themes include SBRT optimization, immunotherapy response monitoring, and radiation toxicity management. American Society of Radiation Oncology (ASTRO) Member Practice locations: UCHealth Radiation Oncology - Anschutz Medical Campus (Aurora, CO) and Rocky Mountain Gamma Knife Center - Anschutz Medical Campus (Aurora, CO) Hospital affiliations: UCHealth Highlands Ranch Hospital and University of Colorado Hospital
University of Texas Southwestern Medical CenterUnited States
Charles L. White is Professor of Pathology at UT Southwestern Medical Center, where he holds the Nancy R. McCune Distinguished Chair in Alzheimer Disease Research. He has served as Director of Neuropathology at UT Southwestern since completing his residency and fellowship training in anatomic pathology and neuropathology at Johns Hopkins in 1983. Dr. White also directs the Neuropathology Core of the UT Southwestern Alzheimer Disease Research Center (established 1988) and the Winspear Family Special Center for Research on the Neuropathology of Alzheimer's Disease (established 2002). Dr. White completed his medical and pathology training at Johns Hopkins University, establishing a career focused on neurodegenerative brain disorders. His educational background forms the foundation for his dual expertise in clinical neuropathology and research investigation. Dr. White's research spans multiple critical areas of neuropathology: Pathological mechanisms of Alzheimer's disease and related dementias Tau protein aggregation and propagation across neurodegenerative conditions Diagnostic criteria and staging systems for various neuropathologies Genetic and molecular underpinnings of frontotemporal lobar degeneration Chronic traumatic encephalopathy and its relationship to other neurodegenerative conditions Development of artificial intelligence approaches for neuropathological assessment Analysis of Dr. White's extensive publication record reveals a consistent focus on defining and characterizing neurodegenerative disease processes through rigorous pathological examination. His work frequently addresses diagnostic criteria, disease classification systems, and the molecular mechanisms underlying various neurodegenerative conditions. There is particular emphasis on tau pathology across multiple disease states, including Alzheimer's disease, primary age-related tauopathy (PART), and chronic traumatic encephalopathy (CTE). His research often involves large collaborative efforts with multiple institutions, reflecting the complex, multidisciplinary nature of modern neuropathological research. Dr. White has received significant recognition for his contributions to the field: Award for Meritorious Contributions to Neuropathology from the American Association of Neuropathologists (2020) Nancy R. McCune Distinguished Chair in Alzheimer Disease Research As an educator and mentor, Dr. White serves as Training Director for the Neuropathology Fellowship program at UT Southwestern, an ACGME-accredited, 2-year training program. Twenty-two trainees have completed the program and become board certified by the American Board of Pathology in the subspecialty of Neuropathology. He has held significant leadership positions including past president of the American Association of Neuropathologists, the national professional organization for neuropathologists in the US. His mentorship extends to numerous research collaborations where he guides junior investigators in neuropathological research methods and interpretation. Dr. White directs multiple research centers including the Neuropathology Core of the UT Southwestern Alzheimer Disease Research Center and the Winspear Family Special Center for Research on the Neuropathology of Alzheimer's Disease. His laboratory work focuses on understanding the pathological mechanisms of neurodegenerative diseases, particularly those involving protein misfolding and aggregation. His team employs advanced techniques including immunohistochemistry, molecular pathology, and increasingly, artificial intelligence approaches to analyze neuropathological specimens.
Memorial Sloan Kettering Cancer CenterUnited States
Ingo K. Mellinghoff is a physician-scientist and Professor at Memorial Sloan Kettering Cancer Center (MSKCC), serving as Chair of the Department of Neurology. He leads the Human Oncology & Pathogenesis Program (HOPP) laboratory, focusing on molecular mechanisms of brain tumor growth, particularly gliomas and primary CNS lymphomas. His work bridges experimental models and clinical trials, emphasizing targeted therapies and liquid biopsy applications. Affiliations: Brain Tumor Center, Gerstner Sloan Kettering Graduate School Research interests include IDH mutations, tumor metabolism, microenvironment interactions, and biomarker-driven trials. Notable achievements include advancing vorasidenib (a mutant IDH inhibitor) to phase 3 trials and developing cerebrospinal fluid-based liquid biopsy techniques for glioma monitoring. Recent articles highlight clinical trial results for IDH inhibitors and translational studies on tumor biology. Awards include the Neuro-Oncology Scientific Award (2023) and membership in prestigious medical societies.
